A
Asier Antoranz
Researcher at Katholieke Universiteit Leuven
Publications - 47
Citations - 1083
Asier Antoranz is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 9, co-authored 31 publications receiving 333 citations. Previous affiliations of Asier Antoranz include National Technical University of Athens.
Papers
More filters
Journal ArticleDOI
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling.
Junbin Qian,Siel Olbrecht,Bram Boeckx,Hanne Vos,Damya Laoui,Emre Etlioglu,Els Wauters,Valentina Pomella,Sara Verbandt,Pieter Busschaert,Ayse Bassez,A. Franken,Marlies Vanden Bempt,Jieyi Xiong,Birgit Weynand,Yannick Van Herck,Asier Antoranz,Francesca Maria Bosisio,Bernard Thienpont,Giuseppe Floris,Ignace Vergote,Ann Smeets,Sabine Tejpar,Diether Lambrechts +23 more
TL;DR: This work profiles 233,591 single cells from patients with lung, colorectal, ovary and breast cancer and constructs a pan-cancer blueprint of stromal cell heterogeneity using different single-cell RNA and protein-based technologies, generating the first panoramic view on the shared complexity of stronal cells in different cancers.
Journal ArticleDOI
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization.
Ana Rita Pombo Antunes,Isabelle Scheyltjens,Francesca Lodi,Julie Messiaen,Asier Antoranz,Johnny Duerinck,Daliya Kancheva,Liesbet Martens,Karen De Vlaminck,Hannah Van Hove,Signe Schmidt Kjølner Hansen,Francesca Maria Bosisio,Koen Van der Borght,Steven De Vleeschouwer,Steven De Vleeschouwer,Raf Sciot,Luc Bouwens,M. Verfaillie,Niels Vandamme,Roosmarijn E. Vandenbroucke,Olivier De Wever,Yvan Saeys,Martin Guilliams,Conny Gysemans,Bart Neyns,Frederik De Smet,Diether Lambrechts,Jo A. Van Ginderachter,Kiavash Movahedi +28 more
TL;DR: This article employed single-cell RNA sequencing and CITE-seq to map the glioblastoma immune landscape in mouse tumors and in patients with newly diagnosed disease or recurrence.
Journal ArticleDOI
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity.
Lore Vanderbeke,P. Van Mol,Y. Van Herck,F. De Smet,Stephanie Humblet-Baron,Kimberly Martinod,Asier Antoranz,Ingrid Arijs,Bram Boeckx,Francesca Maria Bosisio,M. Casaer,Dieter Dauwe,W. De Wever,Christophe Dooms,Erwin Dreesen,A. Emmaneel,J. Filtjens,M. Gouwy,Jan Gunst,Greet Hermans,Steven Jansen,Katrien Lagrou,Adrian Liston,N. Lorent,Philippe Meersseman,Toine Mercier,Johan Neyts,J. Odent,Dena Panovska,P. A. Penttila,E. Pollet,Paul Proost,Junbin Qian,K. Quintelier,Jeroen Raes,S. Rex,Yvan Saeys,Jenny Sprooten,Sabine Tejpar,Dries Testelmans,Karin Thevissen,T. Van Buyten,J. Vandenhaute,S. Van Gassen,L. C. Velásquez Pereira,R. Vos,Birgit Weynand,A. Wilmer,Jonas Yserbyt,Abhishek D. Garg,Patrick Matthys,Carine Wouters,D Lambrechts,Els Wauters,Joost Wauters +54 more
TL;DR: A myeloid-driven immunopathology is suggested, in which hyperactivated neutrophils and an ineffective adaptive immune system act as mediators of COVID-19 disease severity.
Posted ContentDOI
A Pan-Cancer Blueprint of the Heterogeneous Tumour Microenvironment Revealed by Single-Cell Profiling
Junbin Qian,Siel Olbrecht,Bram Boeckx,Hanne Vos,Damya Laoui,Emre Etlioglu,Els Wauters,Valentina Pomella,Sara Verbandt,Pieter Busschaert,Ayse Bassez,A. Franken,Marlies Vanden Bempt,Jieyi Xiong,Birgit Weynand,Yannick Van Herck,Asier Antoranz,Francesca Maria Bosisio,Bernard Thienpont,Giuseppe Floris,Ignace Vergote,Ann Smeets,Sabine Tejpar,Diether Lambrechts +23 more
TL;DR: A first panoramic view on the shared complexity of stromal cells in different cancers is generated by providing a comprehensive blueprint through an interactive web server.
Journal ArticleDOI
Network-based technologies for early drug discovery.
Chris Fotis,Asier Antoranz,Dimitris Hatziavramidis,Theodore Sakellaropoulos,Leonidas G. Alexopoulos +4 more
TL;DR: The traditional drug discovery approach has led to the development of many successful drugs, but the attrition rates remain high and the need for a more-informed and successful implementation of the reductionist, one drug for one target for one disease, approach is recognized.